| _version_ | 1866901494468444160 |
|---|---|
| author | Tripdatabase |
| author_facet | Tripdatabase |
| contents | Transitioning from fedratinib to momelotinib in myelofibrosis patients appears viable based on available evidence, with notable benefits in managing anemia, although direct comparative data between these drugs is limited. |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_20330102 |
| institution | Zenodo |
| language | |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | How do I transition a patient from fedratinib to momelotinib? Tripdatabase fedratinib momelotinib drug transition oncology pharmacology patient management hematologic malignancies myelofibrosis treatment transition Transitioning from fedratinib to momelotinib in myelofibrosis patients appears viable based on available evidence, with notable benefits in managing anemia, although direct comparative data between these drugs is limited. |
| title | How do I transition a patient from fedratinib to momelotinib? |
| topic | fedratinib momelotinib drug transition oncology pharmacology patient management hematologic malignancies myelofibrosis treatment transition |
| url | https://doi.org/10.5281/zenodo.20330102 |